Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 19 04:00PM ET
0.4300
Dollar change
-0.0036
Percentage change
-0.83
%
Index- P/E- EPS (ttm)-9.76 Insider Own18.88% Shs Outstand3.75M Perf Week-1.98%
Market Cap1.61M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float3.04M Perf Month-59.81%
Income-16.99M PEG- EPS next Q- Inst Own12.68% Short Float4.91% Perf Quarter-29.84%
Sales0.00M P/S- EPS this Y- Inst Trans-34.67% Short Ratio0.64 Perf Half Y-42.66%
Book/sh2.45 P/B0.18 EPS next Y- ROA-57.98% Short Interest0.15M Perf Year-88.06%
Cash/sh3.35 P/C0.13 EPS next 5Y4.00% ROE-86.15% 52W Range0.39 - 5.40 Perf YTD-41.90%
Dividend Est.- P/FCF- EPS past 5Y37.15% ROI-121.63% 52W High-92.04% Beta0.78
Dividend TTM- Quick Ratio2.87 Sales past 5Y- Gross Margin- 52W Low10.26% ATR (14)0.06
Dividend Ex-Date- Current Ratio2.87 EPS Y/Y TTM52.81% Oper. Margin0.00% RSI (14)34.10 Volatility8.12% 9.31%
Employees- Debt/Eq0.58 Sales Y/Y TTM- Profit Margin- Recom2.33 Target Price200.00
Option/ShortNo / Yes LT Debt/Eq0.53 EPS Q/Q85.72% Payout- Rel Volume0.38 Prev Close0.43
Sales Surprise- EPS Surprise- Sales Q/Q- Earnings- Avg Volume233.24K Price0.43
SMA20-16.45% SMA50-39.30% SMA200-50.44% Trades Volume88,865 Change-0.83%
Date Action Analyst Rating Change Price Target Change
Feb-12-21Reiterated H.C. Wainwright Buy $15 → $18
Jun-16-20Initiated RBC Capital Mkts Outperform $16
Feb-07-20Initiated Guggenheim Buy
Feb-06-20Initiated Guggenheim Buy
Nov-21-19Initiated Oppenheimer Outperform $14
Sep-24-19Initiated BTIG Research Buy $15
Apr-05-24 04:05PM
Mar-26-24 09:08AM
Nov-27-23 09:00AM
Sep-08-23 07:00AM
Sep-06-23 10:00AM
07:00AM Loading…
Aug-03-23 07:00AM
Jun-30-23 04:05PM
Jun-29-23 08:30AM
Jun-28-23 02:17PM
Jun-14-23 08:30AM
May-24-23 08:00AM
May-22-23 07:00AM
May-16-23 04:01PM
May-11-23 04:15PM
May-02-23 05:00PM
04:10PM Loading…
Feb-14-23 04:10PM
Dec-29-22 05:53PM
Dec-21-22 08:00AM
Oct-21-22 08:00AM
Oct-14-22 04:05PM
Sep-22-22 04:05PM
Aug-11-22 08:00AM
Aug-08-22 09:57AM
Jun-29-22 08:01AM
Jun-01-22 07:00AM
May-17-22 07:00AM
May-12-22 05:00PM
10:53AM
May-02-22 04:30PM
Mar-13-22 07:00PM
08:00AM Loading…
Mar-07-22 08:00AM
Feb-28-22 08:00AM
Feb-10-22 07:00PM
Feb-01-22 10:44AM
Jan-11-22 11:34AM
Jan-10-22 04:02PM
Jan-05-22 04:02PM
Dec-23-21 04:01PM
Nov-03-21 04:05PM
Nov-01-21 01:12PM
Oct-05-21 08:00AM
Sep-28-21 04:05PM
Sep-21-21 04:54PM
Sep-15-21 04:05PM
Sep-14-21 08:00AM
Sep-01-21 04:05PM
Aug-31-21 08:45AM
Aug-12-21 04:01PM
Jun-30-21 05:07AM
Jun-08-21 12:30PM
Jun-02-21 09:00AM
May-25-21 08:00AM
May-20-21 08:00AM
May-14-21 12:31PM
May-13-21 04:05PM
May-12-21 09:00AM
Apr-28-21 04:27AM
Apr-27-21 08:00AM
Apr-26-21 04:01PM
Apr-22-21 09:07AM
Apr-21-21 04:01PM
Apr-14-21 07:00AM
Apr-08-21 08:00AM
Mar-19-21 05:33AM
Mar-16-21 08:00AM
Mar-09-21 07:00AM
Feb-11-21 04:01PM
Jan-28-21 08:00AM
Jan-22-21 12:14AM
Jan-11-21 06:00AM
Dec-23-20 04:05PM
Dec-18-20 11:35AM
Dec-16-20 06:30AM
Dec-02-20 06:23PM
08:00AM
Nov-23-20 08:00AM
Nov-18-20 01:46AM
Nov-17-20 08:00AM
Nov-10-20 08:00AM
Oct-26-20 08:15AM
Oct-20-20 10:09AM
Oct-13-20 08:00AM
Sep-28-20 08:00AM
Sep-17-20 08:30AM
Sep-08-20 08:00AM
Aug-31-20 05:00PM
Aug-24-20 05:00PM
Aug-20-20 01:09PM
Aug-13-20 04:01PM
Aug-06-20 01:43PM
Jun-10-20 04:20PM
May-15-20 08:48AM
Apr-30-20 04:05PM
Apr-28-20 09:44AM
Apr-27-20 04:01PM
Mar-31-20 07:01AM
Dec-02-19 08:00AM
Nov-25-19 08:00AM
Nov-24-19 04:30PM
Nov-12-19 09:16AM
NeuBase Therapeutics, Inc. is a biotechnology company, which engages in the development of drugs for patients with genetic neurological disorders. The firm's therapies are built on a proprietary platform called PATrOL that encompasses a novel peptide-nucleic acid antisense oligonucleotide technology combined with novel delivery shuttles that overcome many of the hurdles to selective mutation engagement, repeat dosing, and systemic delivery of genetic medicines. The company was founded by Dietrich A. Stephan on August 4, 2009 and is headquartered in Pittsburgh, PA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Symetryx Corp10% OwnerSep 14 '23Sale1.44129,108185,916153,337Sep 18 04:32 PM
Symetryx Corp10% OwnerSep 11 '23Sale1.443,3764,861472,926Sep 11 05:08 PM
Symetryx Corp10% OwnerSep 08 '23Sale1.53128,847197,136476,302Sep 11 05:08 PM
Symetryx Corp10% OwnerSep 07 '23Sale1.8074,852134,734605,149Sep 11 05:08 PM
Symetryx Corp10% OwnerSep 01 '23Buy0.9861,07659,732680,081Sep 07 05:19 PM
Stephan Dietrich AFounder and CEOAug 02 '23Option Exercise0.0293,2342,05193,234Aug 04 04:39 PM